Provided by Tiger Trade Technology Pte. Ltd.

Rani Therapeutics Holdings

0.8800
+0.02903.41%
Post-market: 0.8670-0.0130-1.48%19:38 EDT
Volume:708.40K
Turnover:622.71K
Market Cap:122.67M
PE:-4.05
High:0.8974
Open:0.8787
Low:0.8600
Close:0.8510
52wk High:3.87
52wk Low:0.4404
Shares:139.40M
Float Shares:85.67M
Volume Ratio:0.58
T/O Rate:0.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2174
EPS(LYR):-0.4500
ROE:-172.15%
ROA:-52.99%
PB:3.13
PE(LYR):-1.96

Loading ...

Company Profile

Company Name:
Rani Therapeutics Holdings
Exchange:
NASDAQ
Establishment Date:
2012
Employees:
70
Office Location:
2051 Ringwood Avenue,San Jose,California,United States
Zip Code:
95131
Fax:
- -
Introduction:
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Directors

Name
Position
Mir Imran
Chairman, Director
Talat Imran
Director, Chief Executive Officer
Abraham Bassan
Director
Dennis Ausiello
Director
Jean Luc Butel
Director
Lisa Rometty
Director
Vasudev Bailey
Director

Shareholders

Name
Position
Talat Imran
Director, Chief Executive Officer
Svai Sanford
Chief Financial Officer
Eric Groen
General Counsel
Kate McKinley
Chief Business Officer
Mir Hashim
Chief Scientific Officer